Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

The Denmark-based company on Monday said it will offer the first two monthly doses of Wegovy and Ozempic for $199 a month to those who pay in cash between now and March 31 of next year. After those ...

Investing.com -- Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 1.5% on Monday after the health and wellness platform announced a new $250 million share repurchase program. The authorization comes ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

This expansion into diagnostics and tailored care represents a logical strategic extension of the company's telehealth model. Yet, the market's focus remained fixed on the worrying traffic and ...

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a new ...

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

Global populations are aging, a reality that is leading to increased demand for healthcare services, chronic disease ...

The telehealth platform Hims & Hers delivered a jarring third-quarter earnings report that left investors reeling. While the ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...